154P Neoadjuvant chemotherapy plus tislelizumab followed by adjuvant tislelizumab for locoregionally advanced nasopharyngeal carcinoma (NPC): A single-arm, phase II trial

Abstract

Prognosis of NPC with T4 or N3 remains unsatisfactory due to high-risk of distant metastasis. More effective treatment strategies are needed for these patients. GP plus immune checkpoint blockade regimen has been shown to improve the survival in recurrent or metastatic NPC We investigated the efficacy and safety of neoadjuvant with GP plus tislelizumab followed by concurrent chemoradiotherapy, and adjuvant treatment with tislelizumab, an anti-PD-1 monoclonal antibody, in previously untreated T4 or N3 NPC.